SALES P

RESENTATI

ON

DA

NI E

L JO

HN

SO

N

“We are deeply committed to achieving complete customer satisfaction by providing exceptional service and quality products, and cultivating a meaningful rewarding environment for our employees.”

WHY ME? WHY NOW?

THE BOOMERS ARE AGING  

 CDC - The increasing number of older persons, represents a challenge for public health.

Shift to more non-communicable diseases.

The medical community is going to need to keep up, you need me... .

This is where I come in I have the knowledge and sales background within diabetes, urology, and ostomy along with the drive to help educate medical professionals about the Forest Laboratory key products. 

THE BOOMERS ARE AGING - PHARMA ON THE RISECDC - The increasing number of older persons, represents a challenge for public health. In

the United States, approximately 80% of all persons aged >65 years have at least one chronic condition, and 50% have at least two. Diabetes, which causes excess morbidity and increased health-care costs, affects approximately one in five (18.7%) persons aged >65 years, and as the population ages, the impact of diabetes will intensify . The largest increases in diabetes are expected among adults aged >75 years, from 1.2 million women and 0.8 million men in 2000 to 4.4 million women and 4.2 million men in 2050 . As U.S. adults live longer, the prevalence of Alzheimer's disease, which doubles every 5 years after age 65, also is expected to increase

Global Industry Aanalysts - announces the release of a comprehensive global report on the Central Nervous System Therapeutics markets. Global market for CNS Therapeutics is projected to reach US$133 billion by the year 2018, primarily driven by increase in disease prevalence rates due to aging population, introduction of new class of drugs, and increased expenditure on healthcare.

FiercePharma – The number of cancer cases is expected to grow to 22.2 million in 2030, from 12.8 million.

Health Services Research - Certain and inevitable cost pressures result from the fact that the generation of baby boomers is now of the age where their health care needs can be expected to increase significantly every year. Add to this demographic phenomenon that of a steady increase in average longevity and the image of a demographic crisis in health care is not hard to evoke

Reuters - The costs linked to heart failure in the United States are expected to more than double within the next two decades as the population ages and treatments help patients with the disease live longer, a study released on Wednesday found.

WilsonLearning.com - the sheer size of the aging population has produced fear that this “senior boom” could place a significant strain on our nation’s health-care resources, and the pharmaceutical industry will have to grow and adapt accordingly.

MORE ALARMING NEWS – SHIFT TO NON-COMMUNICABLE DISEASES

There has been a shift in the disease pattern from communicable to non-communicable diseases Most non-communicable diseases are chronic in nature, and therefore require long-term treatment. For example, a patient afflicted by diabetes mellitus will probably continue to take anti-diabetic medication for the remainder of their life, while in the case of a patient afflicted with a communicable disease, once the infection is controlled the medication can be discontinued. Non-communicable diseases are therefore major contributors to the growth of the pharmaceutical industry.

Non-communicable diseases include cardiovascular and cerebrovascular diseases, neurodegenerative disorders, metabolic disorders, cancer and stress induced disorders. Predominant cardiovascular diseases include ischemic heart disease and hypertensive heart disease. 

The cardiovascular therapeutic area has historically provided the largest single source of revenue for the pharmaceutical industry. The area is expected to further grow due to high patient populations and a widespread focus on preventative treatment.

Over the next 20 years (2010–2030) in the US, the number of new cancer cases diagnosed annually is anticipated to grow by 45%, from 1.6 million in 2010, to 2.3 million in 2030, with a spike in incidence prediced in the elderly and minority populations.

Diabetes mellitus is the predominant metabolic disorder, which instances of which are increasing noticeably year by year. The worldwide prevalence of type I and type II diabetes, has led the pharmaceutical industry to develop a record number of experimental anti-diabetic drugs. However, failure rates of such drugs remain high due to the complexity of the disease, common side effects, and regulatory hurdles. The standard for new anti-diabetic drugs includes aspects such as: being suitable for both diabetes and obesity; gain long-term glycaemic control; lessen multiple cardio-metabolic risk factors; and bank upon developments in pharmacogenomics. 

 

A ROBUST PIPELINE SET FOR CONTINUED GROWTH FOREST AND ITS PARTNERS ARE DEVELOPING KEY PIPELINE PRODUCTS THAT SPAN A RANGE OF THERAPEUTIC AREAS, INCLUDING CARDIOVASCULAR DISEASE, CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), MENTAL HEALTH CONDITIONS, ALZHEIMER’S DISEASE, INFECTIOUS DISEASE, AND PAIN MANAGEMENT.

COMPOUND AREAS OF INTEREST PHASE I PHASE II PHASE III NDA

CariprazineSchizophrenia/Bipolar Mania

Complete response letter received

Nebivolol* + Valsartan

Hypertension NDA filed

Memantine ER† + Donepezil

Alzheimer's Disease NDA filed

Aclidinium‡ + Formoterol

COPD Phase III completed; NDA being prepared  

Ceftazidime + Avibactam

Infectious Disease Phase III

CariprazineMDD Adjunctive/Bipolar Depression

Phase II    

Cebranopadol (GRT6005)

Pain Management

Phase II    

TRV027Acute Heart Failure

Phase II (with option to license

QUALIFIED EXPERIENCES• Specialty Representative selling of medical services and products

to healthcare professionals and patients. Products include diabetes testing supplies, insulin pump therapy, urological products, incontinence, ostomy, and wound care supplies.

• Builds revenue thru strong collaborative efforts with healthcare professionals, commercial and government payors, and patients to ensure patient satisfaction.

• Achieved revenue goals, production and performance objectives.

• Worked with team of 4 that reached a minimum of $350K monthly by regaining confidence with patients converted back to company.

• Consistently in a leadership position on patient enrollments per day, meeting and exceeding all performance indicators.

• Properly trained sales staff through Quality Assurance and mentoring in order to

receive maximum reimbursement from commercial Medicare and Medicaid payors.

• Put in a Quality Control Roll to mentor and educate staff/team members work, including sales procedures, enrollment, and insurance Informs, patient eligibility, benefits and quality of documentation.

ACCOMPLISHMENTS

• Costco project entailing converting diabetic patients to Johnson and Johnson formularies.

• Worked on revenue based projects converting over new and existing Medtronic insulin pump patients.

• Helped develop and start up the incontinence for regular payment program.

• In urology I reduced the turnaround time for orders from two weeks to two days.

• Developed spreadsheet calculators to quote patient medical and supply costs within the urology department.

• In a Specialty revenue building role that is integrated from department to department.

• Put in a Quality Control Roll to mentor and educate staff/team members work, including sales procedures, enrollment, and insurance Informs, patient eligibility, benefits and quality of documentation.

• Responsible for completing patient product conversions in order to improve product margins.

WINNING ATTRIBUTES

• Prior experience working with Diabetic ,Urology and Ostomy supplies such as Medtronic insulin pumps(Paradigm, Animas, Insulet, Accu-chek), Various test strips, Urology products include open and closed system catheters including all ancillary products

• Motivated by sales driven objectives and goals with focus on success

• Ability to use Strong critical thinking skills to achieve success

• Delivering high customer retention and developing future referrals

• Consistent productivity and sales growth

PRODUCTION SNAPSHOTS – CONSISTENTLY RANKED AT TOP

PRODUCTION SNAPSHOTS – Consistently ranked at top

SALES PROGRESS WITH NORWEGIAN CRUISE LINE

May

June Ju

ly

Augu

st

Sept

e...

Octob

er

Nove.

.. $-

$10,000.00

$20,000.00

$30,000.00

$40,000.00

$50,000.00

$60,000.00

$70,000.00

$80,000.00

Revenue

Bachelor of Business Administration in International Business

Minor in Healthcare AdministrationPROFESSIONAL MEMBERSHIPS

Financial Management AssociationFlorida Atlantic University Pre-Pharmaceutical ClubFlorida Atlantic University Surf Club, Chief Executive Officer O Matter Oakley Product and Sales TrainingDallas Junior Chamber of Commerce Young ProfessionalsDallas Young Professionals – Business Networking